April 5, 2023 from Business Of Cannabis
FRANCE’s medical cannabis pilot programme, which was extended for another year in October 2022, is facing significant supply issues putting patients’ access to treatment in jeopardy.
Suppliers for the ongoing experiment, which was launched in March 2021, are understood to have shunned tender calls to continue their involvement due to significant cost burdens.
According to Newsweed, more than half of the 2,000 patients involved in the scheme have now been left without access to treatment.
With the French government yet to allocate a budget for the programme, or finalise any framework surrounding the regulation of medical cannabis, experts say there is a ‘very big need for a new push to come from the industry supporting patient voices’.